DEA Telemedicine Extension 2026: What EM Providers Need to Know

If you do any telemedicine — locum coverage, a side telemedicine practice, or hybrid ED shifts — the DEA's evolving telemedicine prescribing rules affect what you can prescribe, to whom, and under what conditions. The original framework from the Ryan Haight Act was built for a world that didn't anticipate remote-first care. COVID changed the rules temporarily, and the DEA has spent three years trying to replace those temporary rules with something permanent.

In 2026, the situation is still in motion. Here is what is currently in effect, what has changed since the public health emergency ended, and what you need to have in order if you prescribe controlled substances via telemedicine.

What the Ryan Haight Act Actually Requires

The Ryan Haight Act (2008) was written in response to online pharmacies dispensing controlled substances without legitimate prescriptions. Its core rule: before a practitioner can prescribe a Schedule II–V controlled substance via telemedicine, the patient must have had at least one in-person medical evaluation by that practitioner or an agent of that practitioner.

The Act created narrow exceptions — mainly for DEA-registered hospital-based telemedicine, certain rural health scenarios, and patients already under the care of a DEA-registered practitioner who referred them. But for most outpatient telemedicine encounters, the in-person requirement applied.

The practical effect: a telehealth visit for a Schedule II stimulant, an opioid, or a benzodiazepine required that the prescribing provider had first seen the patient in person.

How COVID Changed the Rules

When the COVID-19 public health emergency (PHE) was declared in March 2020, DEA issued blanket waivers allowing practitioners with a valid DEA registration to prescribe controlled substances via telemedicine without any prior in-person evaluation. No special registration. No prior relationship. Any DEA-registered provider, prescribing via synchronous audio-video telemedicine, could prescribe Schedule II–V controlled substances to patients they had never met in person.

Those waivers stayed in effect through the entirety of the PHE. When the PHE ended on May 11, 2023, the question became: what comes next?

The Extension Period: 2023 Through 2025

Rather than immediately reverting to Ryan Haight Act rules, the DEA issued a series of temporary rules extending COVID-era telemedicine prescribing flexibilities. The timeline:

May 2023: DEA proposed new permanent rules establishing a "telemedicine prescribing registry" — a special registration system that would allow providers to prescribe certain controlled substances via telemedicine without prior in-person evaluation, subject to registration and conditions.

November 2023: The proposed rules drew substantial comment and pushback. DEA extended the COVID flexibilities through December 31, 2024, while it worked on a final framework.

2024: DEA finalized a partial framework but continued to extend full flexibilities while rulemaking proceeded on the remaining provisions.

2025–2026: Revised telemedicine prescribing regulations took effect for most controlled substance categories, with some provisions still subject to ongoing implementation guidance.

Where Things Stand in 2026

The DEA's finalized telemedicine framework in 2026 operates on a tiered system:

Tier 1 — Standard telemedicine prescribing: Prescribers with a valid DEA registration can prescribe Schedule III–V controlled substances via telemedicine to established patients (defined as patients with a qualifying prior clinical relationship) without a new in-person evaluation, subject to the prescriber maintaining appropriate medical records and complying with applicable state law.

Tier 2 — Special Registration for Telemedicine: Providers who want to prescribe Schedule II–III controlled substances to new patients via telemedicine — including stimulants, certain opioids, and benzodiazepines — can apply for a Special Telemedicine Registration with DEA. This registration is separate from a standard DEA registration and involves additional requirements around prescribing logs, patient verification, and recordkeeping.

Hospital/clinic exception: Telemedicine prescribing that occurs as part of a patient's care within a DEA-registered hospital or clinic facility continues to operate under broader permissions, consistent with the original Ryan Haight Act hospital exceptions.

What has not changed: Your underlying DEA registration requirements. You still need an active DEA registration in the state where you are providing telemedicine services (or in the patient's state, depending on the prescribing context). DEA registrations are state-specific, and working across multiple states means maintaining separate registrations.

What EM Providers Actually Need to Manage

Emergency medicine providers run into DEA telemedicine issues in a few recurring scenarios:

Locum telemedicine shifts: If you pick up telemedicine coverage in a state where you are not physically present, you may need a DEA registration for that state. The multi-state DEA registration issue — which Caliber tracks alongside your state licenses — applies to telemedicine exactly as it applies to in-person locum work. One registration per state where you are actively prescribing.

Hybrid ED/telemedicine models: Some EDs now use telemedicine for triage, observation, or extended-care follow-up. If your role includes any of these and you are prescribing controlled substances to patients via telemedicine, confirm whether those encounters are covered by the hospital's DEA registration or require your individual registration.

Standalone telemedicine practices: Providers running or joining telemedicine practices that prescribe controlled substances — particularly mental health platforms prescribing stimulants or buprenorphine — are subject to the DEA Special Registration requirements if prescribing to new patients. This is a separate registration, a separate fee, and a separate renewal cycle from your standard DEA.

Documentation requirements: The finalized DEA telemedicine rules require enhanced documentation for telemedicine-based controlled substance prescriptions. This includes the technology platform used, confirmation that the encounter was audio-visual (not audio-only, in most cases), and the clinical basis for prescribing without a prior in-person evaluation where that exception applies.

The DEA Registration Renewal Problem

Here is where this intersects with Expiration Blindness directly: DEA registrations renew on a 3-year cycle, and telemedicine has dramatically expanded how many DEA registrations some providers hold. Before telemedicine, an EM provider working in one state might hold one DEA registration. A locum provider working in four states holds four registrations — each on its own renewal cycle, each with its own fee, each with its own address and practice site requirements.

The DEA sends renewal notices to the registered address, which may be a practice site you no longer work at. The DEA does not guarantee email delivery. The standard failure mode: a registration expires, you don't notice, and you prescribe on an expired registration — which is a federal violation regardless of whether you were aware.

A provider with multiple DEA registrations across multiple states needs a system that tracks each one independently. Managing this with a spreadsheet or calendar invites exactly the kind of slow drift that ends with an expired registration and a compliance problem.

State Law Still Applies

Federal DEA rules set a floor, not a ceiling. State controlled substance laws and telemedicine prescribing regulations add their own requirements. States like Florida, Ohio, and Texas have their own telemedicine prescribing frameworks that may be more restrictive than federal DEA rules — particularly for new patient encounters and for certain drug categories.

Before prescribing via telemedicine in any state, confirm:

• Whether that state has a telemedicine prescribing law that requires a prior in-person evaluation (some do, independent of DEA rules)
• Whether that state has a controlled substance prescribing exception for telemedicine, and whether your situation qualifies
• Whether your state medical or PA license permits the telemedicine practice you are doing (scope of practice applies to telemedicine as much as in-person)

What to Have in Place

If you are prescribing controlled substances via telemedicine in 2026, the baseline is:

1. Valid DEA registration in every state where patients are located when you prescribe to them
2. Renewal calendar for each DEA registration — dates and addresses must be current
3. Understanding of Special Registration requirements if you are prescribing Schedule II substances to new telemedicine patients
4. State compliance review for each state where you are practicing telemedicine
5. Documentation protocol for telemedicine-based controlled substance encounters that satisfies both DEA and state requirements

The complexity has grown significantly since 2020. Providers who picked up telemedicine work during the PHE and kept it may be holding more DEA registrations than they realize — some of which may be due for renewal or may have lapsed. Running an audit of every active DEA registration you hold is worth doing before it surfaces as a problem.

For EM providers tracking multiple registrations alongside state licenses, specialty certifications, and hospital privileges, the DEA telemedicine rules add another layer to an already complex credential stack. The providers who manage this well are the ones who treat every DEA registration as its own tracked credential — not as an afterthought behind the state license.